Fotemustine
{{drugbox
| IUPAC_name = diethyl (1-{[(2-chloroethyl)(nitroso)carbamoyl]amino}
ethyl)phosphonate
| image = Fotemustine.svg
| CAS_number = 92118-27-9
| ATC_prefix = L01
| ATC_suffix = AD05
| ATC_supplemental =
| PubChem = 104799
| DrugBank = EXPT03300
| C = 9 | H = 19 | Cl = 1 | N = 3 | O = 5 | P = 1
| molecular_weight = 315.691 g/mol
| bioavailability =
| protein_bound =
| metabolism =
| elimination_half-life =
| excretion =
| pregnancy_AU =
| pregnancy_US =
| pregnancy_category =
| legal_AU =
| legal_UK =
| legal_US =
| legal_status =
| routes_of_administration =
}}
|
WikiDoc Resources for Fotemustine |
|
Articles |
|---|
|
Most recent articles on Fotemustine Most cited articles on Fotemustine |
|
Media |
|
Powerpoint slides on Fotemustine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Fotemustine at Clinical Trials.gov Clinical Trials on Fotemustine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Fotemustine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Fotemustine Discussion groups on Fotemustine Patient Handouts on Fotemustine Directions to Hospitals Treating Fotemustine Risk calculators and risk factors for Fotemustine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Fotemustine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
Overview
Fotemustine is a nitrosourea alkylating agent.